• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: New thinking needed for funding, development of future medicines

Report: New thinking needed for funding, development of future medicines

May 8, 2014
CenterWatch Staff

Pharmaceutical scientists are calling for a new covenant to be developed between the pharmaceutical industry and wider society, including government, to accelerate and incentivize the development of new types of tailored medicines and treatments.

A new report by the U.K. Royal Pharmaceutical Society, New Medicines, Better Medicines, Better Use of Medicines, said pharmaceutical companies no longer will be able to rely on “one-size-fits-all” blockbuster medicines for patients.   

Long-term conditions such as heart disease, which currently are managed through the provision of effective but non-curative treatments, are in the sights of scientists who are developing treatments that aim to eradicate, rather than just manage, symptoms in specific groups of patients.  

Professor Jayne Lawrence, RPS chief scientist, said, “We are living in an incredibly exciting age, where the human genome is being decoded and scientists are examining how we can cure diseases rather than just offer symptomatic relief. However, the market is not set up to incentivize the production of new types of medicines. The current crisis in antimicrobial resistance is in part due to the lack of new classes of antibiotics coming on the market. Antibiotics can cure infections in weeks, so the volume of sales of drugs is low. This doesn’t allow the tens or even hundreds of millions required for R&D to be recouped.” 

“We need the NHS to be able to cope with funding treatments which have a high initial cost but may not require a lifetime of use by patients,” said Lawrence. “Unless we find a way to develop treatments that cure illnesses in months, rather than treat symptoms for years, we will not see the breakthroughs that both scientists and patients want.”

Kevin Shakesheff, professor of advanced drug delivery and tissue engineering, University of Nottingham, said, “Future medicines will be highly personalized, for example, using stem cells and regenerative drugs to treat patients after a stroke, heart attack or spinal cord injury. These treatments will transform medicine but we face major hurdles getting them into widespread clinical use. They present new problems in manufacturing, safety and economics and require new ways of working across disciplines in order to accelerate commercial and clinical success.”

Richard Bergström, director general, European Federation of Pharmaceutical Industries and Associations, said, “There is a lot of excitement in my industry about all the targeted medicines that are in the pipeline. However, there also is concern that the regulatory requirements and way forward for developing new drugs are not clear. We need the regulators to move with the science and update their guidelines as our understanding of disease changes. We have a duty to deliver the new science to patients as quickly as possible. Both regulators and organizations that pay for drugs need to come together and jointly consider what evidence should be developed.”  

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing